Gene variant influences risk for blood clots in COVID patients

A gene variant in the natural immune system influences the risk for blood clots in the lungs of severely ill COVID-19 patients. This has been documented in a new study by researchers at Uppsala University and Karolinska Institutet that has now been published in Nature Immunology.

“With this study, we are a step closer in explaining why COVID-19 patients have a substantially increased risk of blood clots,” says Oskar Eriksson, medical doctor and researcher at Uppsala University and one of the article’s main authors.

It became apparent during the pandemic that patients with COVID-19 had a substantial increased risk of suffering blood clots, even when treated with blood thinners. Why COVID-19 leads to such a major activation of the blood’s coagulation system in some patients is not yet clear. Researchers at Uppsala University and Karolinska Institutet have now discovered that a gene variant, which regulates the levels of the protein mannose-binding lectin in the blood, protects against blood clots in the lungs.

Recognizes the coronavirus

Mannose-binding lectin is part of the natural immune system. It discovers and eliminates cells infected by bacteria and viruses. Another recent study (Stravalaci et al. Nature Immunology volume 23, pages 275–286 (2022)) showed that mannose-binding lectin recognizes the SARS-CoV-2 virus that causes COVID-19 and can neutralize cells infected with the virus.

“We can now show how mannose-binding lectin influences the course of the illness COVID-19. It is striking that it is the risk for blood clots that is impacted, and we could not see that mannose-binding lectin influences the risk of becoming ill with COVID-19. We can show that the immune system is important for blood clot formation in COVID-19 patients, something that was long suspected and that can explain why such high doses of blood thinners have been necessary,” says Oskar Eriksson.

Source: Read Full Article